ClinicalTrials.gg
Not yet recruitingNCT07581860GHRB-CUpdated Aug 6, 2026

Growth Hormone Resistance of Beta-cells

An observational study in Healthy, Obesity & Overweight and Impaired Fasting Glucose (IFG), sponsored by University of Missouri-Columbia. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by University of Missouri-Columbia · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10
Ages
18 Years to 59 Years
Sex
All
01

Study summary

The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with impaired fasting glucose or impaired glucose tolerance at the University of Missouri. The aim of the study is to advance understanding of how growth hormone affects beta-cells and risk factors for developing type 2 diabetes.

02

Conditions studied

  • Healthy
  • Obesity & Overweight
  • Impaired Fasting Glucose (IFG)
  • Impaired Glucose Tolerance (Prediabetes)
03

In context

Obesity

11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.

This study's planned enrollment of 10 is below the median of 114 across 2,154 observational studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

University of Missouri-Columbia is the lead sponsor of 365 studies on the registry; 69 are open to participants now.

Of its 43 completed or terminated interventional studies of FDA-regulated products, 29 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will consist of lean and obese people ages 18-59 with impaired fasting glucose or impaired glucose tolerance.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >18.5kg/m2 and \<45.9kg/m2
  • impaired fasting glucose >/= 100mg/dL, \</= 126mg/dL or impaired glucose tolerance on 75g oral glucose tolerance test (blood glucose 140 to 199mg/dL at two-hours)

Exclusion criteria

Exclusion Criteria:

  • pregnant, planning to become pregnant during the study, or breastfeeding
  • current diagnosis or history of type 1 or type 2 diabetes
  • use of medications that can impact the study outcomes (e.g., GLP-1 receptor agonists)
  • history of bariatric surgery
  • known, uncontrolled hypothyroidism
  • history of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as Turner Syndrome, Prader-Willi Syndrome, or renal impairment
  • current cancer or cancer that has been in remission less than 5 years
  • first degree relative with type 1 diabetes
  • evidence of anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease)
  • alcohol use disorder, use of controlled substances, or smoking >2 cigarettes per day
  • greater than 3% weight loss within three months of screening or engaged in regular (>/= 3 days per week), continuous moderate- or high-intensity exercise of >/= 30 min duration
  • mentally disabled persons, prisoners, and persons with inability to grant voluntary
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10 participants (estimated)
Patient registry
No

Groups and cohorts

  • Impaired fasting glucose
  • Impaired glucose tolerance
06

What researchers measure

Primary outcomes

  1. Beta-cell function

    Insulin secretion rate in relationship to plasma glucose

    Time frame: before and 7 days after rhGH administration

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — De-identified data will be available upon reasonable request

Time frame: 5 years after completion of the study

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07581860
Responsible party
Bettina Mittendorfer (Senior Associate Dean for Research; Professor, Medicine & Nutrition; NextGen Director of Clinical and Translational Sciences Unit, University of Missouri-Columbia) — Principal investigator
First posted
May 12, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Sep 1, 2028 (estimated)
Completion
Sep 1, 2030 (estimated)
Last update
Aug 6, 2026

Study contacts

Study Coordinator
Contact
ahmc4@health.missouri.edu
573-884-6852
Vasavi Shabrish
Contact
v.shabrish@missouri.edu
Bettina Mittendorfer
principal investigator · University of Missouri-Columbia

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion